Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax

References

• Centers for Disease Control and Prevention. Anthrax vaccine recommendations. 2016 [accessed 2023 Oct 11]. https://www.cdc.gov/vaccines/vpd/anthrax/hcp/recommendations.html#:~:text=CDC%20recommends%20a%20post%2Dexposure,to%20aerosolized%20Bacillus%20anthracis%20spores.
   Google Scholar
• Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond). 1956;54(1):28–7. doi:10.1017/S0022172400044272.
   PubMedGoogle Scholar
• Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, et al. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob Agents Chemother. 2006;50(11):3535–42. doi:10.1128/AAC.00090-06.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Howard C, Hunter-Stitt E, Kaptur PE, Pleune B, Muse D, Sheldon E, Davis M, Strout C, Vert-Wong K. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax(R) regimen for post-exposure prophylaxis in healthy adults. Vaccine. 2014;32:2217–2224. doi:10.1016/j.vaccine.2014.01.073.
   PubMed Web of Science ®Google Scholar
• Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW. Enhanced early innate and T cell-mediated responses in subjects immunized with anthrax vaccine adsorbed plus CPG 7909 (AV7909). Vaccine. 2014;32:6847–6854. doi:10.1016/j.vaccine.2014.01.096.
   PubMed Web of Science ®Google Scholar
• FDA. [accessed 2023 July 26]. https://www.fda.gov/media/170463/download?attachment.
   Google Scholar
• Savransky V, Shearer JD, Gainey MR, Sanford DC, Sivko GS, Stark GV, Li N, Ionin B, Lacy MJ, Skiadopoulos MH. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine. 2017;35(37):4952–9. doi:10.1016/j.vaccine.2017.07.076.
   PubMed Web of Science ®Google Scholar
• Shearer JD, Henning L, Sanford DC, Li N, Skiadopoulos MH, Reece JJ, Ionin B, Savransky V. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Vaccine. 2021;39(1):1–5. doi:10.1016/j.vaccine.2020.10.095.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Vaccine. 2016;34(18):2096–105. doi:10.1016/j.vaccine.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Wolfe DN, Espeland EM, Gao Y, Lu D, Blatner G, Amass K, Horwith G, Tong XM, Hopkins R, David GL, et al. Evaluation of BioThrax(R) and AV7909 anthrax vaccines in adults 66 years of age or older. Vaccine. 2020;38:7970–7976. doi:10.1016/j.vaccine.2020.10.053.
   PubMed Web of Science ®Google Scholar
• Rankin R, PPontarollo R, Ioannou X, Krieg AM, Hecker R, BBabiuk LA, van Drunen Littel-van den Hurk S. CpG Motif Identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001;11(5):333–40. doi:10.1089/108729001753231713.
   PubMedGoogle Scholar
• Savransky V, Sanford DC, Syar E, Austin JL, Tordoff KP, Anderson MS, Stark GV, Barnewall RE, Briscoe CM, Lemiale-Bierinx L, et al. Pathology and pathophysiology of inhalational anthrax in a guinea pig model. Infect Immun. 2013;81(4):1152–63. doi:10.1128/IAI.01289-12.
   PubMed Web of Science ®Google Scholar
• Perry MR, Ionin B, Barnewall RE, Vassar ML, Reece JJ, Park S, Lemiale L, Skiadopoulos MH, Shearer JD, Savransky V. Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines. Vaccine. 2020 Feb 28;38(10):2307–14. doi:10.1016/j.vaccine.2020.01.068.
   PubMed Web of Science ®Google Scholar
• Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL Jr., Stark GV, Innes A, Sari S, et al. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol. 2013;20(7):1016–26. doi:10.1128/CVI.00099-13.
   PubMed Web of Science ®Google Scholar
• Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, et al. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol. 2012;19(11):1730–45. doi:10.1128/CVI.00324-12.
   PubMed Web of Science ®Google Scholar
• Chen L, Schiffer JM, Dalton S, Sabourin CL, Niemuth NA, Plikaytis BD, Quinn CP, Staats HF. Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques. Clin Vaccine Immunol. 2014;21(11):1512–20. doi:10.1128/CVI.00469-14.
   PubMed Web of Science ®Google Scholar
• Pitt MLM, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 2001;19(32):4768–73. doi:10.1016/S0264-410X(01)00234-1.
   PubMed Web of Science ®Google Scholar
• Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, et al. Humoral and cell-mediated immune responses to alternate booster schedules of anthrax vaccine adsorbed in humans. Clin Vaccine Immunol. 2016;23(4):326–38. doi:10.1128/CVI.00696-15.
   PubMedGoogle Scholar
• Schiffer JM, Chen L, Dalton S, Niemuth NA, Sabourin CL, Quinn CP. Bridging non-human primate correlates of protection to reassess the anthrax vaccine adsorbed booster schedule in humans. Vaccine. 2015;33(31):3709–16. doi:10.1016/j.vaccine.2015.05.091.
   PubMed Web of Science ®Google Scholar
• Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, et al. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis. 2007;195(2):174–84. doi:10.1086/510312.
   PubMed Web of Science ®Google Scholar
• Schlesinger RB. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health. 1985;15(2):197–214. doi:10.1080/15287398509530647. PMID: 3892021.
   PubMed Web of Science ®Google Scholar